There is something surreal about watching television and seeing an advertisement for a cancer drug. A patient is walking on a beach. A family is laughing around a dinner table. Someone is gardening in beautiful afternoon light. A soothing voice explains that a drug with an almost unpronounceable name may help people with metastatic cancer live longer. Then comes the obligatory rapid-fire list of potentially serious adverse events. And somewhere in America, presumably, a cancer patient is expected to think: I should ask my oncologist about that. That premise is increasingly absurd.
Newly diagnosed cancer patients are too often thrust into a world of confusing medical information and advice. In market research, I’ve listened to both patients and caregivers, and they are confused and look to HCPs for direction and advice. However, they also conduct a lot of online research about their disease, including treatment options. They want to better understand what is happening and what could happen with treatments. In the back of their minds is someone without hair, looking frail, trying to navigate daily tasks. What has pharma done? Added to the confusion.
We advertise oncology drugs as if patients were choosing between brands of allergy medication. But cancer treatment doesn’t work that way. A patient with lung, breast, prostate, colorectal, or another cancer isn’t simply diagnosed with “cancer” and handed a menu of drugs. Treatment increasingly depends on tumor type, stage, histology, biomarkers, genomic alterations, previous therapies, comorbidities, performance status, treatment goals, and an expanding body of clinical evidence.
The actual conversation sounds less like “ask your doctor if Drug X is right for you” and more like: What did the pathology show? What’s the biomarker status? Is there an actionable mutation? What’s the line of therapy? What do the guidelines recommend? What does insurance cover?
Yet pharma companies continue spending enormous amounts of money marketing oncology brands directly to consumers.
Who exactly is being persuaded?
This is where the logic starts falling apart. If I see an advertisement for a pickup truck, I can go buy the truck. If I see an advertisement for a restaurant, I can make a reservation. Even with many prescription drugs, a patient may have considerable influence over the choice. Cancer drugs are different.
The oncologist controls the prescription, but even the oncologist doesn’t operate in a vacuum. Pathology, molecular testing, FDA labeling, clinical guidelines, prior authorization, formulary restrictions, infusion-center protocols, and sometimes tumor boards can shape treatment choices.
So what exactly is the television commercial supposed to accomplish? Presumably it creates awareness and encourages patients to ask about a particular therapy. But imagine being newly diagnosed with metastatic cancer. You’re frightened. You’re trying to understand survival statistics, scans, biomarkers, and treatment options while simultaneously figuring out how to tell your family what is happening.
Then pharma marketing enters the room and essentially says: Have you considered our brand? That isn’t patient empowerment. It’s consumer marketing awkwardly grafted onto one of medicine’s most complicated areas.
The emotional component makes it even stranger
Oncology advertising doesn’t merely sell awareness. It frequently sells imagery. Sunlight. Families. Vacations. Birthdays. Ordinary moments reclaimed from cancer. There is a reason for that. You cannot meaningfully explain a modern oncology treatment in a 60-second commercial. The clinical reality is too complicated. So the advertisement communicates something much easier to understand: hope.
Hope is enormously powerful when someone has cancer. And that’s precisely why pharmaceutical companies should be extraordinarily careful about commercializing it.
A patient watching an advertisement rarely has enough information to evaluate the magnitude of clinical benefit. “Living longer” can mean very different things depending on the trial, endpoint, and patient population. Progression-free survival isn’t overall survival. Relative risk reduction isn’t absolute benefit. A statistically significant result isn’t necessarily a transformational one for every patient.
Those distinctions matter enormously in oncology. They also make terrible television commercials.
Imagine spending the money somewhere else
Here is the bigger question pharmaceutical executives should be asking:
What if some of the money spent persuading cancer patients to recognize a brand were spent helping them understand their disease?
Imagine an oncology company funding genuinely useful, brand-neutral education explaining biomarkers, genomic testing, treatment sequencing, clinical trials, second opinions, and the questions patients should ask after diagnosis. Imagine helping patients understand why two people with what appears to be the same cancer can receive completely different treatments. Imagine investing more heavily in tools that help patients navigate prior authorization, find appropriate clinical trials, understand financial assistance, or prepare for an oncology appointment.
That would create something much more valuable than brand awareness. It would create informed patients.
Pharma is marketing to the wrong person
For oncology brands, the most consequential audience remains the healthcare ecosystem that makes and implements the treatment decision.
Oncologists need credible clinical evidence. Pathologists and testing laboratories need clarity around biomarkers. Payers need health-economic evidence. Oncology nurses need practical information about administration and adverse-event management. Medical Science Liaisons need to engage clinicians in sophisticated scientific discussions. Patients need understandable education and support.
Those are fundamentally different communications challenges. Trying to solve the patient component with a glossy television commercial is a relic of mass-market pharmaceutical marketing. And it may become increasingly ridiculous as oncology becomes more personalized.
The future of cancer treatment is moving toward greater precision: the right treatment, for the right tumor biology, in the right patient, at the right point in the disease. The advertising model is moving in the opposite direction: broadcast the same simplified message to millions of people, almost none of whom are clinically appropriate candidates. That’s the contradiction.
Nobody diagnosed with cancer needs Madison Avenue to tell them to care about surviving. They need physicians they trust, accurate information they can understand, access to appropriate testing, transparency about benefits and risks, and help navigating an extraordinarily complicated healthcare system.
Maybe oncology companies should spend less money telling cancer patients to “ask your doctor about our drug.” And spend more money making sure patients understand what to ask their doctor in the first place.
